A new Parkinson’s drug failed to meet expectation in a recent clinical trial despite showing initial promise. The failure dashed hopes among those seeking improved treatment for the disease.
Parkinson’s is a degenerative disorder of the central nervous system. Early symptoms can affect motor skills, often manifesting as rigidity, tremors, and slowness of movement. Behavioral and cognitive difficulties can affect sufferers as the disease progresses.
Phytopharm, a biotech company based in Britain, held high hopes for its Parkinson’s drug Cogane. Intended to treat the early stages of the disease, the drug performed well during first phase clinical studies.
Reuters reports that, with the creation of Cogane, Phytopharm was striving to pioneer a new class of therapy treatment for disorders such as “neurodegenerative diseases, motor neuron disease, and glaucoma.” However, Cogane failed as a viable treatment during its second phase study.
According to The Guardian, over 400 patients in the early stages of Parkinson’s participated in the trial and received either placebo or Cogane. Results indicated that the Cogane group experienced no significant statistical improvement over those who were given the placebo.
Warren Olanow, Professor of Neurology and Neuroscience at Mount Sinai Medical School and co-chief Investigator for the study, remarked on the results:
“This is disappointing news for the Parkinson disease community. The company is to be congratulated for carrying out this important study in such a high quality manner. Sadly, the results are negative. Nonetheless, the search for more effective therapies for the millions of patients who suffer from Parkinson’s disease must continue.”